The addition of Synthorx will help add strength to Sanofi’s immuno-oncology pipeline.
Sanofi, a French multinational pharmaceutical company, has announced the acquisition of Synthorx, a US a clinical-stage biotech company focused on therapies for people with cancer and autoimmune disorders. The approximately $2.5 billion acquisition is aimed at strengthening Sanofi’s immuno-oncology pipeline. It will benefit Sanofi with the addition of Synthorx’s THOR-707, an immuno-oncology product candidate, and other earlier-stage cytokine programs. According to Sanofi’s recent press release, the acquisition is expected to close in Q1 2020, following the satisfaction or waiver of customary closing conditions. Sanofi will acquire all of Synthorx’s outstanding shares for around $68 per share in cash, as per the terms of the agreement signed between the two companies.
“Our company is grateful that Sanofi has acknowledged the potential of Synthorx’s pipeline of optimized therapeutics for autoimmune disorders and cancer and the value of Synthorx’s Expanded Genetic Alphabet platform. Sanofi, importantly, has a therapeutics portfolio holding remarkable promise for combining with our cytokine Synthorins for benefiting patients across the globe. I want to thank the Sanofi organization and Synthorx employees for their persistent efforts on behalf of patients,” said President and CEO of Synthorx, Laura Shawver, Ph.D.
Synthorx’s platform to enable Sanofi to develop wide range of novel biologics
“The acquisition perfectly fits with Sanofi’s strategy to lead with innovation and create a portfolio of high-quality assets, as you’ll hear at Sanofi’s Capital Markets Day on December 10, tomorrow. In addition, it’s aligned with Sanofi’s goal to build our oncology franchise with novel combinations and potentially practice-changing medicines,” said CEO of Sanofi, Paul Hudson.
The addition of Synthorx’s Expanded Genetic Alphabet platform will enable Sanofi to develop a broad array of novel biologics having applications not just in oncology but also other therapeutic fields. This could be possible with the use of Synthorx’s Expanded Genetic Alphabet platform alone or in combination with Sanofi’s other existing platforms, which include the Nanobody technology. An interleukin-2 variant, THOR-707 has the potential to demonstrate therapeutic superiority, less frequent dosing, and enhanced pharmacology compared to other interleukin-2 compounds, according to Sanofi’s recent press release. It also has the potential to become the best-in-class interleukin-2 therapeutic for treating solid tumors.